<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02569372</url>
  </required_header>
  <id_info>
    <org_study_id>GC1102B_P1</org_study_id>
    <nct_id>NCT02569372</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients</brief_title>
  <official_title>A Prospective, Open-label, Dose-escalation, Single-center, Phase I Trial to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of GC1102 (Recombinant Hepatitis B Human Immunoglobulin)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is SAD(Single Ascending Dose)/MAD(Multiple Ascending Dose) study to Explore the
      Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of GC1102 (Recombinant Hepatitis B
      Human Immunoglobulin) in Chronic Hepatitis B Patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GC1102 is a new recombinant hepatitis B human immunoglobulin. This study is composed with 2
      Parts, Part A for SAD and Part B for MAD and total 4 dosing program which is escalated after
      confirming safety. Maximum 48 subjects will be participated in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2015</start_date>
  <completion_date type="Actual">October 12, 2017</completion_date>
  <primary_completion_date type="Actual">October 12, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity after the administration of GC1102</measure>
    <time_frame>Part A: 4weeks, Part B: 7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events after the administration of GC1102</measure>
    <time_frame>Part A: 4weeks, Part B: 7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical findings in physical examination, vital signs and clinical laboratory after the administration of GC1102</measure>
    <time_frame>Part A: 4weeks, Part B: 7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBsAg sero-conversion rate from positive to negative after the administration of GC1102 till End of Study visit</measure>
    <time_frame>Part A: 4weeks, Part B: 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer of serum HBsAg at each measurement point after the administration of GC1102</measure>
    <time_frame>Part A: 4weeks, Part B: 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer of serum HBV DNA of each measurement point after the administration of GC1102</measure>
    <time_frame>Part A: 4weeks, Part B: 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence rate of anti-GC1102 antibody</measure>
    <time_frame>Part A: 4weeks, Part B: 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence rate of HBV DNA sequence changes after the administration of GC1102</measure>
    <time_frame>Part A: 4weeks, Part B: 7 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Ctrough for Part B</measure>
    <time_frame>7 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Terminal elimination half-life (t½β)</measure>
    <time_frame>Part A: 4weeks, Part B: 7 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the time concentration curve from 0 to last and infinity (AUClast, AUC0-∞)</measure>
    <time_frame>Part A: 4weeks, Part B: 7 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maximum plasma concentration(Cmax)</measure>
    <time_frame>Part A: 4weeks, Part B: 7 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Part A: 4weeks, Part B: 7 weeks</time_frame>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>GC1102 80,000 IU(Single does)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1102 80,000 IU(Single does) I.V.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC1102 120,000 IU(Single does)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1102 120,000 IU(Single does) I.V.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC1102 180,000 IU(Single does)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1102 180,000 IU(Single does) I.V.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC1102 240,000 IU(Single does)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1102 240,000 IU(Single does) I.V.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC1102 80,000 IU(Multiple does)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1102 80,000 IU(Multiple does) I.V.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC1102 120,000 IU(Multiple does)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1102 120,000 IU(Multiple does) I.V.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC1102 180,000 IU(Multiple does)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1102 180,000 IU(Multiple does) I.V.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC1102 240,000 IU(Multiple does)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1102 240,000 IU(Multiple does) I.V.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC1102</intervention_name>
    <description>GC1102(Recombinant Hepatitis B Human Immunoglobulin)</description>
    <arm_group_label>GC1102 80,000 IU(Single does)</arm_group_label>
    <arm_group_label>GC1102 120,000 IU(Single does)</arm_group_label>
    <arm_group_label>GC1102 180,000 IU(Single does)</arm_group_label>
    <arm_group_label>GC1102 240,000 IU(Single does)</arm_group_label>
    <arm_group_label>GC1102 80,000 IU(Multiple does)</arm_group_label>
    <arm_group_label>GC1102 120,000 IU(Multiple does)</arm_group_label>
    <arm_group_label>GC1102 180,000 IU(Multiple does)</arm_group_label>
    <arm_group_label>GC1102 240,000 IU(Multiple does)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic hepatitis B or those who diagnosed with chronic hepatitis B
             carrier who given written informed consent.

          -  Patients aged ≥19 and ≤ 65 years

          -  If Naïve for the Nucleos(t)ide analogs therapy, HBeAg (-), HBsAg 1,000 IU/mL or less
             and HBV DNA 2,000IU/mL or less Or If currently receiving Nucleos(t)ide analogs
             therapy, HBeAg (±), HBsAg 1,000 IU/mL or less and HBV DNA (-: limit of detection of 60
             IU/mL or less).

        Exclusion Criteria:

          -  Patients who currently involved or has participated in any other clinical trial within
             30 days.

          -  Patients co-infected with HAV, HCV or HIV

          -  Patients with history of malignant tumor within 5 years except basal cell carcinoma of
             skin, cervical intraepithelial neoplasia.

          -  Patients who have active infection except chronic hepatitis infection.

          -  Patients with liver disease who had complications such as gastroesophageal variceal,
             ascites and hepatic encephalopathy.

          -  Having eGFR 59 mL/min/1.73m2 or less with MDRD Evaluation phase (moderate reduction in
             GFR or more )

          -  Having blood or protein 1+ or more by the urine analysis with microscopic examination.

          -  Patients who have a clinically significant kidney disease including
             glomerulonephritis, anuria, acute renal failure, dialysis and renal transplantation.

          -  Patients with Vasculitis.

          -  Having leukocytes &lt;3.0 x109/L

          -  Having Absolute Neutrophil Count&lt;1.5x109/L

          -  Having platelet &lt;750,000/mm3 during screening

          -  Having hemoglobin &lt;10g/dL

          -  Having positive sign of serum cryoglobulin level.

          -  Having serum anti-nuclear antibody (ANA) 1:160 or more

          -  Patients who showed positive sign of serum perinuclear anti-Neutrophil Cytoplasmic
             Antibodies (p-ANCA).

          -  Patients who showed positive sign of serum cytoplasmic anti-Neutrophil Cytoplasmic
             Antibodies (c-ANCA).

          -  Patients who had history or be suspected of immune disease

          -  Patients who had experienced cardiovascular attack, myocardiac infarction, heart
             failure, PTCA or coronary artery bypass, angina, arrhythmia, any other clinically
             meaningful valvular heart disease, cerebral infarction or cerebral hemorrhage within 6
             months.

          -  Patients who had history of anaphylaxis against the main component or subcomponent of
             study drug.

          -  Patients who had been administered live vaccine parentally (measles vaccine, parotitis
             vaccine, rubella vaccine, cholera combined vaccine, varicella vaccine) within 3 months
             prior to the dosing of study drug.

          -  Patients who had been received an immunosuppressant, immunity-modifying drug including
             interferon agents, cytotoxic chemotherapy that can affect their immune system, or
             radiation therapy within 3 months prior to the dosing of study drug

          -  Patients who had been treated with any other immunoglobulin within 3 months prior to
             the dosing of study drug

          -  Patients who had been treated with systemic steroid Therapy(more than 20 mg/day of
             prednisolone or its equivalence administered every day for more than 14 days, or more
             than 700 mg of a cumulative dose during the same period of time) within 3 months prior
             to the dosing of study drug (topical administration such as topical ointments, eye
             drops, inhalants or intranasal use, intra-articular injection, or tendon injection is
             acceptable; alternative-day treatment is acceptable even though administered for more
             than 14 days)

          -  Women who showed positive sign of pregnancy test before administered study drug.

          -  Those who do not agree to use appropriate contraceptive methods (condom, diaphoretic,
             an intrauterine device, oral contraceptive hormones, or a vasectomy of male sex
             partner) during the clinical trials.

          -  Those who had experienced bleeding more 400ml or a blood donation within 8 weeks prior
             to the dosing of study drug.

          -  Those who had been abused alcohol or any other drug within 6 months.

          -  Those who are judged disqualified to join clinical trials by investigator for other
             clinically significant medical or psychiatric condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Hoon An, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chin Kim</last_name>
    <role>Study Director</role>
    <affiliation>Green Cross Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2015</study_first_posted>
  <last_update_submitted>October 13, 2017</last_update_submitted>
  <last_update_submitted_qc>October 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

